The European Health Organization has announced that it has received a request from the American pharmaceutical company Gilad Science to approve its anti-retroviral drug, Remdisifer, as a possible treatment for corona virus in Europe..According to a Reuters report, the European Medicines Agency said in a statement: “The benefits and risks of the drug are evaluated and an opinion can be issued within weeks.”
The European Health Organization has pledged to conduct a rapid review of a possible remediffer drug for the treatment of people with coronavirus, owned by the American company Gilad Science, and the European Medicines Agency said (EMA) The timetable of the Human Medicines Committee for Medication Evaluation “will be reduced to a minimum, and this announcement comes two weeks after the President of the European Health Organization notified the European Parliament that he might give a tentative green light to sell Remsdevir as a treatment for coronaviruses, especially as there is currently no drug or vaccine Certified for severe infection and sometimes fatal.
The United States, the world’s largest drug market, earlier this month granted a license to use Remisfer in emergency cases of Coronavirus, paving the way for wider use of the drug, but it has not yet been approved..
The European Medicines Agency reviewed the drug periodically and suggested a beneficial effect in treating hospital patients with mild to moderate or severe Covid 19..
On the other hand, the Swiss pharmaceutical company, Roche, announced that it intends to test whether the combination of its anti-arthritis drug Actemra With Gilad America’s REMDISVER anti-viral treatment, it works better against corona virus and knowing that this combination helps treat serious complications of Covid 19..
Where it is used Actemra And remdesivir Separately in some environments and clinical trials, with the previous drug being used to treat massive immune reactions that sometimes occur in patients with the new coronavirus and the latter aims to interfere with viral reproduction.
– .
